 Home > Encyclopedia > Pimavanserin

Pimavanserin

Pimavanserin structure

CAS No:
706779-91-1
Formula:
C25H34FN3O2
Chemical Name:
Pimavanserin
Synonyms:
Urea,N-[(4-fluorophenyl)methyl]-N-(1-methyl-4-piperidinyl)-N′-[[4-(2-methylpropoxy)phenyl]methyl]-;N-[(4-Fluorophenyl)methyl]-N-(1-methyl-4-piperidinyl)-N′-[[4-(2-methylpropoxy)phenyl]methyl]urea;Pimavanserin;N-(4-Fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-[[4-(2-methylpropyloxy)phenyl]methyl]carbamide;Nuplazid;1-[(4-Fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea;1-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea
Categories:
Pharmaceutical Intermediates > Bulk Drug Intermediates

Description

Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC50 and pKd of 8.73 and 9.3, respectively.

Pimavanserin is a member of the class of ureas in which three of the four hydrogens are replaced by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropyloxy)benzyl groups. An atypical antipsychotic that is used (in the form of its tartrate salt) for treatment of hallucinations and delusions associated with Parkinson's disease. It has a role as an antipsychotic agent, a 5-hydroxytryptamine 2A receptor inverse agonist and a serotonergic antagonist. It is a member of ureas, a member of piperidines, a member of monofluorobenzenes, an aromatic ether and a tertiary amino compound. It is a conjugate base of a pimavanserin(1+).|Pimavanserin (ACP-103), marketed under the trade name Nuplazid, is a drug developed by Acadia Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and no significant affinity or activity at 5-HT2B or dopamine receptors. As of September 3, 2009, pimavanserin has not met expectations for Phase III clinical trials for the treatment of Parkinson's disease psychosis. It is in Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication and is expected to improve the effectiveness and side effect profile of antipsychotics. The results of a clinical trial examining the efficacy, tolerability and safety of adjunctive pimavanserin to risperidone and haloperidol were published in November 2012 and the results showed that pimavanserin potentiated the antipsychotic effects of subtherapeutic doses of risperidone and improve the tolerability of haloperidol treatment by reducing the incidence of extrapyramidal symptoms. On September 2, 2014, the United States Food and Drug administration granted Breakthrough Therapy status to Acadia's New Drug Application for pimavanserin.|Pimavanserin is an Atypical Antipsychotic.|Pimavanserin is an atypical antipsychotic used in the treatment of hallucinations and psychosis in patients with Parkinson disease. Use of pimavanserin is associated with a low rate of serum enzyme elevations during therapy, and it has not been linked to instances of clinically apparent acute liver injury.

Pimavanserin Basic Attributes

Molecular Weight：

427.55

Exact Mass：

427.55

EC Number：

1806241-263-5

UNII：

JZ963P0DIK

DSSTox ID：

DTXSID50220958

ATC Code：

N - Nervous system

HScode：

29339900

Characteristics

PSA：

44.8

XLogP3：

4.67

Appearance：

Pale Yellow to Pale Orange Solid

Density：

1.1±0.1 g/cm3

Melting Point：

100-103 ºC

Boiling Point：

604.2±55.0 °C at 760 mmHg

Flash Point：

319.2±31.5 °C

Refractive Index：

1.576

Storage Conditions：

Refrigerator

Safety Information

safety instructions：

24/25

Marks：

GHS Classification：

|Danger|H302+H332 (100%): Harmful if swallowed or if inhaled [Warning Acute toxicity, oral; acute toxicity, inhalation]|P261, P264, P270, P271, P272, P280, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P310, P312, P321, P330, P333+P313, P363, and P501|Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Hepatotoxicity：

Liver test abnormalities are uncommon (

Drug Information

Drug Indication：

Investigated for use/treatment in neurologic disorders, parkinson's disease, psychosis, schizophrenia and schizoaffective disorders, and sleep disorders.|Treatment of schizophrenia and other psychotic disorders

LiverTox Summary：

Pimavanserin is an atypical antipsychotic used in the treatment of hallucinations and psychosis in patients with Parkinson disease. Use of pimavanserin is associated with a low rate of serum enzyme elevations during therapy, and it has not been linked to instances of clinically apparent acute liver injury.

Drug Classes：

Antipsychotic Agents

MeSH：

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)|Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)|Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes. (See all compounds classified as Serotonin 5-HT2 Receptor Antagonists.)

Mechanism of Action：

ACP-103 reduces haloperidol-induced akathisia, a debilitating extrapyramidal side effect (EPS), in patients with schizophrenia. ACP-103 is a 5-HT2A inverse agonist, to reduce the side effects associated with antipsychotic drug treatment with haloperidol. ACP-103 reduced both the motor disturbances and hyperprolactinemia, a condition of elevated prolactin secretion, caused by haloperidol treatment.

MeSH Entry Terms：

ACP 103

Pimavanserin Use and Manufacturing

Uses

Drug used in the treatment of Parkinson’s disease psychosis.

Use Classification：

Human Drugs -> EU pediatric investigation plans

Computed Properties

Molecular Weight:427.6
XLogP3:4.5
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:8
Exact Mass:427.26350550
Monoisotopic Mass:427.26350550
Topological Polar Surface Area:44.8
Heavy Atom Count:31
Complexity:523
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of Pimavanserin

Greenbo Biochem Contact Supplier

CN
5 YRS

Business licensed Certified factory

Manufactory Supplier of Active Pharm Ingredients,Chemical Catalyst,Pharmaceutical Intermediates,Flavors and Fragrances,Agrochemicals,Chemical Pesticides,Organic Intermediates,OLED Intermediates

Pimavanserin 99% Pharm Intermediate Professional Producer Greenbo

CAS No.: 706779-91-1

Grade: Pharmaceutical Grade

Content: 99%

Inquiry
Hefei Heyu Chemical New Materials Co., Ltd Contact Supplier

CN
4 YRS

Business licensed

Trader Supplier of 13-Dimethyladamantane,1-Bromo-35-dimethyladamantane,perhydroacenaphthylene,4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol,CYCLOBUTANE-1,2-DICARBOXYLIC ACID DIMETHYL ESTER, TRANS

Pimavanserin 706779-91-1

CAS No.: 706779-91-1

Inquiry
Henan Lihao Chem Plant Limited Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of PVC resin,pvc paste resin,melamine

Pimavanserin 99% see COA kanbei

CAS No.: 706779-91-1

Grade: Industrial Grade

Content: 99%

Inquiry
NewRoute Pharma Contact Supplier

CN
2 YRS

Business licensed

Trader Supplier of Avibactam Sodium,Blonanserin,Relebactam,Tofacitinib

Pimavanserin

CAS No.: 706779-91-1

Grade: Pharmaceutical Grade

Inquiry